Explore / Clinical trial
Clinical trial

A Long-term Comparison of Esketamine Nasal Spray Versus Quetiapine Extended Release, Both in Combination With a Selective Serotonin Reuptake Inhibitor/Serotonin-Norepinephrine Reuptake Inhibitor, in Participants With Treatment Resistant Major Depressive Disorder

Janssen-Cilag International NVCompletedPhase 3Started Aug 21, 2020676 enrolledArgentina, Austria, Belgium, Brazil, Bulgaria, Czechia, Denmark, Finland, Germany, Greece, Hungary, Israel, Kazakhstan, Malaysia, Netherlands, Norway, Poland, Portugal, South Africa, South Korea, Sweden, Taiwan, Turkey (Türkiye), United Arab EmiratesNCT04338321

Abstract

The primary purpose of this study is to evaluate the efficacy of flexibly dosed esketamine nasal spray compared with quetiapine extended-release (XR), both in combination with a continuing selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor (SSRI/SNRI), in achieving remission in participants who have treatment-resistant major depressive disorder (MDD) with a current moderate to severe depressive episode.

Topics & conditions

Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.

KetamineDepression

Keywords

Depressive Disorder, Major

Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.